Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 3, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain a comprehensive financial performance update for the period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not include financial statements or key performance indicators.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The only changes disclosed relate to the ownership of Ordinary Shares by directors and the GSK Trust.
Management Commentary and Risks
Management commentary is restricted to the disclosure of share acquisitions under Personal Equity Plans and transfers from the GlaxoSmithKline Employee Trust. No outlook, risks, contingencies, or unusual items are discussed in this filing.
Important Facts for Investors
- Trust Transfer: The GSK Trust transferred 3,334 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on July 1, 2003.
- Director Acquisitions: Several directors acquired beneficial interests in Ordinary Shares on July 1, 2003, at a price of £12.23 per share:
- Sir Christopher Hogg: 45 shares
- Mr J D Coombe: 13 shares
- Mrs G A Coombe (wife of Mr J D Coombe): 9 shares
- Sir Peter Job: 2 shares
- Reporting Limitation: This filing does not contain financial results; investors should refer to the company's Form 20-F or interim reports for financial data.